DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0045|270-4137|15|1790-1801

ISSN： 0270-4137

Source： THE PROSTATE, Vol.270-4137, Iss.15, 2015-11, pp. : 1790-1801

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence

By  

THE PROSTATE, Vol. 75, Iss. 15, 2015-11 ,pp. : 1790-1801

John Wiley & Sons Inc

Access to resources Recommend Favorite

[11C]Choline PET/CT for Targeted Salvage Lymph Node Dissection in Patients with Biochemical Recurrence after Primary Curative Therapy for Prostate Cancer

By  

Urologia Internationalis, Vol. 81, Iss. 2, 2008-08 ,pp. : 191-197

Karger

Access to resources Recommend Favorite

Prospective study of DNA methylation at LINE‐1 and Alu in peripheral blood and the risk of prostate cancer

By  

THE PROSTATE, Vol. 75, Iss. 15, 2015-11 ,pp. : 1718-1725

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prospective study of DNA methylation at LINE‐1 and Alu in peripheral blood and the risk of prostate cancer

By  

THE PROSTATE, Vol. 270-4137, Iss. 15, 2015-11 ,pp. : 1718-1725

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate‐risk prostate cancer treated using radical prostatectomy

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 11, 2015-11 ,pp. : 1029-1035

John Wiley & Sons Inc

Access to resources Recommend Favorite